-
公开(公告)号：US20140336185A1
公开(公告)日：2014-11-13
申请号：US14122176
申请日：2012-05-31
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Thomas Fowler , Andrew Novak , Premji Meghani , Enugurthi Brahmachary , Adam Richard Yeager
IPC分类号： C07C235/38 , C07D307/54 , A61K31/341 , C07D213/80 , A61K31/4406 , C07D211/34 , A61K31/4465 , C07D295/15 , A61K31/5375 , C07D239/26 , A61K31/505 , A61K31/495 , C07D295/24 , A61K31/54 , A61K31/235
CPC分类号： A61K31/4245 , A61K9/0019 , A61K9/0095 , A61K31/155 , A61K31/235 , A61K31/341 , A61K31/4406 , A61K31/4439 , A61K31/4465 , A61K31/4725 , A61K31/495 , A61K31/505 , A61K31/5375 , A61K31/54 , A61K38/22 , A61K38/26 , A61K45/06 , A61K47/20 , A61K47/26 , A61K47/40 , A61K47/6951 , B82Y5/00 , C07C229/14 , C07C233/47 , C07C233/51 , C07C233/81 , C07C233/83 , C07C235/12 , C07C235/38 , C07C235/48 , C07C237/22 , C07C237/36 , C07C237/42 , C07C255/57 , C07C271/28 , C07C275/42 , C07C311/08 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/48 , C07C317/28 , C07C317/44 , C07C323/62 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/267 , C07D209/08 , C07D211/14 , C07D211/34 , C07D211/62 , C07D213/55 , C07D213/65 , C07D213/79 , C07D213/80 , C07D213/81 , C07D213/82 , C07D215/48 , C07D217/02 , C07D231/12 , C07D233/60 , C07D235/06 , C07D235/12 , C07D235/18 , C07D239/26 , C07D239/28 , C07D239/74 , C07D239/91 , C07D241/42 , C07D241/44 , C07D249/08 , C07D257/04 , C07D261/18 , C07D263/32 , C07D263/34 , C07D263/48 , C07D263/57 , C07D271/06 , C07D271/07 , C07D271/107 , C07D277/30 , C07D277/56 , C07D277/66 , C07D279/12 , C07D295/15 , C07D295/155 , C07D295/205 , C07D295/24 , C07D307/24 , C07D307/54 , C07D307/68 , C07D307/79 , C07D309/06 , C07D309/08 , C07D311/16 , C07D317/68 , C07D333/38 , C07D413/04 , C07D413/12 , C07D417/12 , C08B37/0015 , C08L5/16 , A61K2300/00
摘要： Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP (1-42), PTH (1-34), Glucagon (1-29), GLP-2 (1-33), GLP-1 (7-36), GLP-1 (9-36), oxyntomodulin and exendin variants.
摘要翻译： 结合胰高血糖素样肽1（GLP-1）受体的化合物，其合成方法，其治疗和/或预防用途的方法及其在体外稳定GLP-1受体中用于GLP- 1受体。 某些化合物自身或存在受体配体如GIP（1-42），PTH可能具有作为胰高血糖素受体，GIP受体，GLP-1和GLP-2受体以及PTH受体的调节剂或增效剂的活性 （1-34），胰高血糖素（1-29），GLP-2（1-33），GLP-1（7-36），GLP-1（9-36），胃泌酸调节蛋白和毒蜥外泌肽变体。
-
公开(公告)号：US20130178420A1
公开(公告)日：2013-07-11
申请号：US13712624
申请日：2012-12-12
申请人： RECEPTOS, INC.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： C07D413/14 , A61K31/4245 , C07D413/10 , A61K31/454 , A61K31/4545 , A61K31/4709 , C07D239/26 , A61K31/505 , C07D413/12 , A61K31/506 , C07D403/12 , C07D403/04 , C07D243/08 , A61K31/551 , A61K38/26 , C07D271/06
CPC分类号： C07K5/06113 , A61K31/33 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/05 , A61K38/26 , A61K45/06 , C07D211/22 , C07D233/54 , C07D233/60 , C07D239/26 , C07D239/34 , C07D241/08 , C07D243/08 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/24 , C07D277/30 , C07D285/08 , C07D285/12 , C07D291/00 , C07D401/04 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译： 本发明涉及调节胰高血糖素样肽1（GLP-1）受体的化合物，其合成方法及其治疗和/或预防用途的方法。 这些化合物独立地用作GLP-1受体的调节剂或增强剂，或者作为受体配体包括GLP-1肽GLP-1（7-36）和GLP-1（9-36）或与基于肽的疗法 ，其中A，B，C，Y 1，Y 2，Z，R 1，R 2，R 3，R 3，R 3，R 3， R4，R5，W1，n，p和q如本文所定义。
-
公开(公告)号：US20160228450A1
公开(公告)日：2016-08-11
申请号：US14965777
申请日：2015-12-10
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs , Daniel Glynn , Mark Mills
IPC分类号： A61K31/551 , C07D271/06 , A61K31/4245 , C07D413/04 , A61K31/4545 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/454 , C07D271/107 , C07D263/32 , A61K31/421 , C07D277/30 , A61K31/426 , C07D285/12 , A61K31/433 , C07D285/08 , C07D239/26 , A61K31/505 , A61K31/506 , C07D413/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D495/04 , C07D403/04 , C07D401/04 , C07D239/34 , C07D241/08 , A61K31/495 , A61K31/4178 , C07D211/98 , A61K31/4468 , A61K31/445 , C07D211/22 , C07D207/08 , A61K31/402 , C07D243/08 , C07D213/55 , A61K31/44 , C07D241/12 , A61K31/4965 , C07D237/08 , A61K31/50 , C07D253/065 , A61K31/53 , A61K31/501 , A61K31/497 , C07D409/14 , A61K38/26
CPC分类号： A61K31/551 , A61K31/402 , A61K31/4178 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/4468 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/495 , A61K31/4965 , A61K31/497 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/53 , A61K38/26 , C07D207/08 , C07D211/22 , C07D211/98 , C07D213/55 , C07D215/14 , C07D231/12 , C07D237/08 , C07D239/26 , C07D239/34 , C07D239/74 , C07D241/08 , C07D241/12 , C07D243/08 , C07D253/06 , C07D253/065 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/30 , C07D285/08 , C07D285/12 , C07D295/084 , C07D295/135 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D495/04
摘要： Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
-
公开(公告)号：US09260427B2
公开(公告)日：2016-02-16
申请号：US14302260
申请日：2014-06-11
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： C07D403/10 , A61K31/506 , C07D471/04 , C07D403/12 , C07D401/04 , C07D403/04 , C07D239/26 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D271/06 , C07D495/04 , C07D231/12 , C07D233/64 , C07D243/08 , C07D413/14 , C07D417/04
CPC分类号： C07D495/04 , A61K31/155 , A61K31/415 , A61K31/4164 , A61K31/4245 , A61K31/4453 , A61K31/4985 , A61K31/505 , A61K31/506 , A61K31/551 , C07D231/12 , C07D233/64 , C07D237/04 , C07D239/26 , C07D243/08 , C07D271/06 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D471/04
摘要： Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译： 提供调节胰高血糖素样肽1（GLP-1）受体的化合物及其合成方法及其治疗和/或预防用途的方法。 这些化合物本身可以作为GLP-1受体的调节剂或增效剂，或者可以作为降解素肽如GLP-1（7-36）和GLP-1（9-36），或者基于肽的疗法，例如 艾塞那肽和利拉鲁肽，具有以下通用结构（其中“”表示化合物的R和S形式中的任一者或两者）：其中A，B，C，Y1，Y2，Z，R1，R2，R3，R4，R5 ，W1，n，p和q如本文所定义。
-
公开(公告)号：US09187522B2
公开(公告)日：2015-11-17
申请号：US14296907
申请日：2014-06-05
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： A61K31/33 , C07K5/072 , C07D233/54 , C07D233/60 , C07D401/04 , C07D403/04 , C07D239/26 , C07D239/34 , C07D409/12 , C07D413/04 , C07D241/08 , C07D417/12 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D495/04 , C07D277/24 , C07D285/12 , C07D211/22 , A61K31/4245 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/26 , C07D243/08 , C07D403/12 , C07D413/10 , C07D413/12 , C07D413/14 , A61K45/06 , C07D291/00 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K38/05 , C07D277/30 , C07D285/08
CPC分类号： C07K5/06113 , A61K31/33 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/05 , A61K38/26 , A61K45/06 , C07D211/22 , C07D233/54 , C07D233/60 , C07D239/26 , C07D239/34 , C07D241/08 , C07D243/08 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/24 , C07D277/30 , C07D285/08 , C07D285/12 , C07D291/00 , C07D401/04 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译： 本发明涉及调节胰高血糖素样肽1（GLP-1）受体的化合物，其合成方法及其治疗和/或预防用途的方法。 这些化合物独立地用作GLP-1受体的调节剂或增强剂，或者作为受体配体包括GLP-1肽GLP-1（7-36）和GLP-1（9-36）或与基于肽的疗法 ，其中A，B，C，Y 1，Y 2，Z，R 1，R 2，R 3，R 3，R 3，R 3， R4，R5，W1，n，p和q如本文所定义。
-
公开(公告)号：US20140031290A1
公开(公告)日：2014-01-30
申请号：US13936815
申请日：2013-07-08
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Liming Huang , Junko Tamiya , Mark T. Griffith , Thomas Fowler , Andrew Novak , Michael Knaggs , Premji Meghani
IPC分类号： A61K38/02 , A61K31/24 , A61K45/06 , A61K31/455 , C07D213/82 , C07D333/38 , A61K31/381 , C07D307/68 , A61K31/34 , C07D307/85 , A61K31/343 , C07D261/18 , A61K31/42 , C07D277/62 , A61K31/428 , C07D241/44 , A61K31/498 , C07D295/155 , A61K31/5375 , C07C235/84
CPC分类号： A61K38/02 , A61K31/24 , A61K31/34 , A61K31/343 , A61K31/381 , A61K31/42 , A61K31/428 , A61K31/455 , A61K31/498 , A61K31/5375 , A61K45/06 , C07C233/87 , C07C235/52 , C07C235/84 , C07C237/36 , C07C237/42 , C07C255/57 , C07C275/42 , C07C317/44 , C07D207/44 , C07D211/62 , C07D213/56 , C07D213/82 , C07D215/48 , C07D231/14 , C07D233/90 , C07D241/44 , C07D257/06 , C07D261/18 , C07D261/20 , C07D263/48 , C07D265/30 , C07D277/62 , C07D277/82 , C07D285/14 , C07D295/15 , C07D295/155 , C07D307/66 , C07D307/68 , C07D307/85 , C07D309/08 , C07D317/60 , C07D333/38 , C07D333/70 , C07D471/04
摘要： Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for use in structural analyses of the GLP-1 receptor. Methods of synthesis, methods of therapeutic and/or prophylactic use, and methods of use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor of such compounds are provided.
摘要翻译： 提供了结合胰高血糖素样肽1受体（GLP-1）受体的化合物，包括作为GLP-1受体的调节剂的化合物和能够诱导对受体的稳定作用的化合物，用于GLP的结构分析 -1受体。 提供了合成方法，治疗和/或预防用途的方法，以及用于稳定GLP-1受体体外用于结合这些化合物的GLP-1受体的方法。
-
公开(公告)号：US20130231326A1
公开(公告)日：2013-09-05
申请号：US13740661
申请日：2013-01-14
申请人： RECEPTOS, INC.
发明人： Esther Martinborough , Marcus F. Boehm , Adam Richard Yeager , Junko Tamiya , Liming Huang , Enugurthi Brahmachary , Manisha Moorjani , Gregg Alan Timony , Jennifer L. Brooks , Robert Peach , Fiona Lorraine Scott , Michael Allen Hanson
IPC分类号： C07D271/06 , A61K31/496 , A61K31/454 , A61K31/4245 , C07C311/13 , A61K31/427 , C07C245/14 , A61K45/06 , C07D413/12 , C07D417/12 , C07D413/14 , A61K31/5377 , C07C255/58
CPC分类号： C07D271/06 , A61K31/4245 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K45/06 , C07C245/14 , C07C255/58 , C07C311/13 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12
摘要： Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.
-
公开(公告)号：US09474755B2
公开(公告)日：2016-10-25
申请号：US14809020
申请日：2015-07-24
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： C07D401/10 , C07D403/10 , A61K31/506 , C07D403/06 , C07D403/14 , C07D409/12 , C07D409/14 , A61K38/05 , C07D401/14 , C07D471/08 , C07K5/078
CPC分类号： A61K38/05 , A61K31/155 , A61K31/4985 , A61K31/506 , A61K31/7004 , C07D401/10 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/14 , C07D409/10 , C07D409/12 , C07D409/14 , C07D471/08 , C07K5/06139 , A61K2300/00
摘要： Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, R1, R2, R3, R4, R5, n, p and q are as defined herein.
-
公开(公告)号：US20150038416A1
公开(公告)日：2015-02-05
申请号：US14296907
申请日：2014-06-05
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： C07K5/072 , A61K45/06 , A61K31/4245 , C07D413/14 , A61K31/4545 , C07D413/04 , A61K31/4439 , A61K31/4709 , A61K38/05 , C07D277/30 , A61K31/426 , C07D285/08 , A61K31/433 , C07D239/26 , A61K31/505 , C07D271/06
CPC分类号： C07K5/06113 , A61K31/33 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/05 , A61K38/26 , A61K45/06 , C07D211/22 , C07D233/54 , C07D233/60 , C07D239/26 , C07D239/34 , C07D241/08 , C07D243/08 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/24 , C07D277/30 , C07D285/08 , C07D285/12 , C07D291/00 , C07D401/04 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译： 本发明涉及调节胰高血糖素样肽1（GLP-1）受体的化合物，其合成方法及其治疗和/或预防用途的方法。 这些化合物独立地用作GLP-1受体的调节剂或增强剂，或者作为受体配体包括GLP-1肽GLP-1（7-36）和GLP-1（9-36）或与基于肽的疗法 ，其中A，B，C，Y 1，Y 2，Z，R 1，R 2，R 3，R 3，R 3，R 3， R4，R5，W1，n，p和q如本文所定义。
-
公开(公告)号：US09598430B2
公开(公告)日：2017-03-21
申请号：US14958513
申请日：2015-12-03
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： C07D403/10 , A61K31/506 , C07D495/04 , C07D403/12 , C07D401/04 , C07D403/04 , C07D239/26 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D271/06 , C07D231/12 , C07D233/64 , C07D243/08 , C07D413/14 , C07D417/04 , C07D471/04 , A61K31/155 , A61K31/415 , A61K31/4164 , A61K31/4245 , A61K31/4453 , A61K31/4985 , A61K31/505 , A61K31/551 , C07D237/04 , C07D401/12 , C07D403/14 , C07D413/10
CPC分类号： C07D495/04 , A61K31/155 , A61K31/415 , A61K31/4164 , A61K31/4245 , A61K31/4453 , A61K31/4985 , A61K31/505 , A61K31/506 , A61K31/551 , C07D231/12 , C07D233/64 , C07D237/04 , C07D239/26 , C07D243/08 , C07D271/06 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D471/04
摘要： Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.05 秒)
